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   This study focused on metabolic remodeling of mitochondrial electron transport 
chain under hypoxia/hyponutrition and highly reactive oxygen species (hROS) 
generation following ischemia-reperfusion (IR). The following results have been 
obtained in the study: 
1.    This study established a specific, rapid, and reproducible assay system for 
succinate concentration. This method is unique in that it is a cycling assay and 
because of this, is more sensitive than conventional ones.  
2.    Using the assay, this study evaluated the intra- and extracellular succinate 
concentration of DLD-1, Panc-1, and HDF cells. Under 1% O2/glc(-)gln(-), the 
quinol–fumarate reductase (QFR) activity of complex II (succinate:ubiquinone 
reductase) increases, becoming the major source of succinate accumulation.  
3.    By using respiratory chain (RC) inhibitors, two major sources of electrons 
leading to succinate accumulation under 1% O2/glc(-)gln(-) were identified as 
complex I and dihydroorotate dehydrogenase (DHODH).  
4.    By combining the novel succinate determination assay and specific detection of 
hROS by Aminophenyl Fluorescein, this study also investigated the involvement of 
succinate onto hROS production and provided a direct evidence that mitochondrial 
complex II and possibly DHODH are the responsible hROS production site at 30 
min following IR-mimicking condition and complex I has little role in hROS 
production.. 
  
These results suggest that under tumour microenvironment, “metabolic remodeling” 
occurs, in which electron flow alters from classical oxygen respiration to fumarate 
respiration, and that this remodeled metabolism becomes essential to support NADH 
re-oxidation as well as nucleotides biosynthesis. This study has also attained the 
profound insights into succinate-driven hROS production in cultured human cells. 
Revealing the mechanism involved in succinate accumulation as well as 
succinate-mediated hROS production can provide leading drug candidates for treatment 
of a range of disorders including tumours and IR injury. Thus, this study has a major 
contribution and deserves the degree. 
 
